Katie E. O' Sullivan

Dr. Katie E. O' Sullivan


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
GMGillian Moore
Gillian Moore
CLClara Lightner
Clara Lightner
SESamira Elbai
Samira Elbai
LBLauren Brady
Lauren Brady
SNSiobhan Nicholson
Siobhan Nicholson
Kathy GatelyKathy Gately
Kathy Gately
PIM kinases are constitutively active proto-oncogenic serine/threonine kinases that play a role in cell cycle progression, metabolism, inflammation and drug resistance. PIM kinases interact with and stabilize p53, c-Myc and parallel signaling pathway PI3K/Akt. This study evaluated PIM kinase expression in NSCLC and in response to PI3K/mTOR inhibition. It investigated a novel preclinical PI3K/mTOR/PIM inhibitor (IBL-301) in vitro and in patient-derived NSCLC tumor tissues. Western blot analysis confirmed PIM1, PIM2 and PIM3 are expressed in NSCLC cell lines and PIM1 is a marker of poor prognosis in patients with NSCLC. IBL-301 decreased PIM1, c-Myc, pBAD and p4EBP1 (Thr37/46) and peIF4B (S406) protein levels in-vitro and MAP kinase, PI3K-Akt and JAK/STAT pathways in tumor tissue explants. IBL-301 significantly decreased secreted pro-inflammatory cytokine MCP-1. Altered mRNA expression, including activated PIM kinase and c-Myc, was identified in Apitolisib resistant cells (H1975GR) by an IL-6/STAT3 pathway array and validated by Western blot. H1975GR cells were more sensitive to IBL-301 than parent cells. A miRNA array identified a dysregulated miRNA signature of PI3K/mTOR drug resistance consisting of regulators of PIM kinase and c-Myc (miR17-5p, miR19b-3p, miR20a-5p, miR15b-5p, miR203a, miR-206). Our data provides a rationale for co-targeting PIM kinase and PI3K-mTOR to improve therapeutic response in NSCLC.

Verified
Journal Article
Open access
PDF file
KSKatie E. O' Sullivan
Katie E. O' Sullivan
AMAdriana J. Michielsen
Adriana J. Michielsen
EREsther O’ Regan
Esther O’ Regan
MCMary C. Cathcart
Mary C. Cathcart
GMGillian Moore
Gillian Moore
Jacintha O' SullivanJacintha O' Sullivan
Jacintha O' Sullivan
Signal transducers and activator of transcription (STAT)-3 is activated in cancers, where it promotes growth, inflammation, angiogenesis, and inhibits apoptosis. Tissue microarrays were generated using tissues from 154 patients, with oesophageal adenocarcinoma (OAC) (n = 116) or squamous cell carcinoma (SCC) (n = 38) tumours. The tissues were stained for pSTAT3 and IL-6R using immunohistochemistry. The OE33 (OAC) and OE21 (SCC) cell lines were treated with the STAT3 inhibitor, STATTIC. The Univariate cox regression analysis revealed that a positive pSTAT3 in SCC was adversely associated with survival (Hazard ratio (HR) 6.382, 95% CI 1.266–32.184), while a protective effect was demonstrated with the higher pSTAT3 levels in OAC epithelium (HR 0.74, 95% CI 0.574–0.953). The IL-6R intensity levels were higher in the SCC tumours compared with the OAC tumours for the core and leading edge tumour tissue. The pSTAT3 levels correlated positively with the IL-6R levels in both the OAC and SCC. The treatment of OE21 and OE33 cells with the STAT3 inhibitor STATTIC in vitro resulted in decreased survival, proliferation, migration, and increased apoptosis. The pSTAT3 expression was associated with adverse survival in SCC, but not in the OAC patients. The inhibition of STAT3 in both of the tumour subtypes resulted in alterations in the survival, proliferation, migration, and apoptosis, suggesting a potential role for therapeutically targeting STAT3.

1 January 2024 in Journal of Cardiac Surgery
Verified
Journal Article
Open access
KSKatie E. O' Sullivan
Katie E. O' Sullivan
LCLaura Casey
Laura Casey
PSPushpinder Sidhu
Pushpinder Sidhu
AGAlastair Graham
Alastair Graham
CAChristopher Austin
Christopher Austin
MHMichael Hunter
Michael Hunter
As surveillance and the diagnosis of pathology grow, increasing numbers of patients are undergoing major aortic interventions globally. As a result, surgeons and physicians will encounter thoracic aortic graft infections with increasing frequency. These infections are extremely challenging, high‐risk problems to deal with. This article provides a comprehensive overview of the pathogenesis, diagnosis, and management both medical and surgical of this high‐risk complication. We provide proposed diagnostic criteria and suggested algorithm for the management of this important group of patients.

1 December 2023 in European Journal of Cardio-Thoracic Surgery
Verified
Journal Article
Closed access
PDF file
KSKatie E. O' Sullivan
Katie E. O' Sullivan
Katie E O’Sullivan; Prophylactic epicardial pacemaker implantation in tricuspid valve replacement surgery; a commentary, European Journal of Cardio-Thoracic Sur

25 June 2018 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
KSKatie E. O' Sullivan
Katie E. O' Sullivan
RFRobert Fleck
Robert Fleck
GVGaia Vigano
Gaia Vigano
GFGerard J. Fitzmaurice
Gerard J. Fitzmaurice
PCPaul Cullen
Paul Cullen
LNLars Nölke
Lars Nölke

6 April 2021 in Irish Journal of Medical Science (1971 -)
Verified
Journal Article
Closed access
PDF file
KSKatie E. O' Sullivan
Katie E. O' Sullivan
SCSusan Cull
Susan Cull
LALara Armstrong
Lara Armstrong
AMAine McKendry
Aine McKendry
AGAlastair N. J. Graham
Alastair N. J. Graham